Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $5.05 and traded as low as $4.98. Aldeyra Therapeutics shares last traded at $5.03, with a volume of 359,642 shares trading hands.
Aldeyra Therapeutics Stock Down 2.8 %
The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The firm's 50-day moving average price is $5.00 and its 200 day moving average price is $5.06.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.25). As a group, equities research analysts forecast that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Aldeyra Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALDX. State Street Corp boosted its holdings in Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company's stock worth $5,249,000 after buying an additional 16,188 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in shares of Aldeyra Therapeutics by 163.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company's stock valued at $2,571,000 after acquiring an additional 295,864 shares during the period. Barclays PLC boosted its stake in Aldeyra Therapeutics by 280.1% during the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company's stock worth $353,000 after acquiring an additional 48,313 shares during the last quarter. International Assets Investment Management LLC grew its holdings in Aldeyra Therapeutics by 397.0% during the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company's stock valued at $15,480,000 after purchasing an additional 229,487 shares during the period. Finally, US Bancorp DE bought a new stake in Aldeyra Therapeutics in the third quarter valued at approximately $30,000. Institutional investors own 59.71% of the company's stock.
Aldeyra Therapeutics Company Profile
(
Get Free Report)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Featured Articles
Before you consider Aldeyra Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aldeyra Therapeutics wasn't on the list.
While Aldeyra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
